Publications

FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance

Quoted, Life Science Leader

Kurt Erskine, Government Investigations Chair, discusses why companies should continue to comply with the FCPA, despite the DOJ's pause on FCPA enforcement.